Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial
. Anaemia as Predictor of All-Cause Mortality in Patients with Systolic Dysfunction. Biomed Data J. 2015;1(3):51-55.
National Library of Medicine (brackets, no "et al."): . Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. European Journal of Heart Failure. 2009;11(8):795 - 801.
National Library of Medicine (grant proposals with PMCID/PMID): . Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. European Journal of Heart Failure. 2009;11(8):795 - 801.
National Library of Medicine (NLM) - Grant with PMID: . Design of the Reduction of Events with Darbepoetin alfa in Heart Failure (RED-HF): a Phase III, anaemia correction, morbidity-mortality trial. European Journal of Heart Failure. 2009;11(8):795 - 801.
